All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
This article is a case report written by Hiroshi Ureshino and his colleagues from Division of Hematology, Saga University, Japan published in Internal Medicine in August 2016; discussing rituximab-induced acute thrombocytopenia (RIAT), a rare complication of rituximab administration which was experienced by a 65 year old male patient after receiving rituximab for the treatment of high tumor burden follicular lymphoma in the leukemic phase.
The key points of the article are as follows:
RIAT has been rarely reported in patients with NHL and its mechanism remains uncertain. However, it is interesting to note that that RIAT has been also reported in rare cases of hairy cell leukemia (a chronic B-cell lymphoid leukemia) and autoimmune hemolytic anemia, in which splenomegaly was also observed. The main speculations for the patient to develop RIAT were perhaps (a) due to FL cells infiltrating into the spleen (and other organs), (b) rituximab rapidly eradicating lymphoma cells and the sub-endothelium getting exposed to flowing blood, (c) cytokines being released from normal and neoplastic lymphocytes and endothelial cells affecting the integrity of the endothelial barrier, and (d) the endothelial disruption inducing platelet activation and aggregation, leading to transient acute thrombocytopenia, which recovered with endothelial repair. Future clinical trials and their respective set of data would help to establish whether RIAT is a lymphoma-specific complication or whether it can occur in various disease conditions.
The full article can be found here
Rituximab induced acute thrombocytopenia in high tumor burden follicular lymphoma
Rituximab-induced acute thrombocytopenia (RIAT), a rare complication of rituximab administration, has not yet been described in follicular lymphoma (FL). A 65-year-old man received rituximab for the treatment of high tumor burden follicular lymphoma in the leukemic phase. The next day, his platelet count abruptly dropped from 85,000 to 5,000/μL, which spontaneously recovered in a few days without specific treatment. We speculate that the occurrence of infusion-related cytokine release syndrome in rituximab-sensitive high tumor burden FL contributed to the development of RIAT. Frequent monitoring of the platelet count is advisable for select patients considered to be at a high risk for RIAT.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox